Home / VEGF-C / Recombinant Human VEGF-C Protein

Recombinant Human VEGF-C Protein

Catalog #: 2179-VC
25 Citations 2 Reviews Datasheet / COA / SDS
Newer Version Available: 9199-VC
NEW
To be discontinued when inventory is sold. The replacement is catalog # 9199-VC

Discontinued Product

2179-VC has been discontinued and is replaced by 9199-VC.

R&D Systems Recombinant Proteins and Enzymes
1 Image
Product Details
Citations (25)
FAQs
Reviews (2)
Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human VEGF-C Protein Summary

Product Specifications

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured in a cell proliferation assay using HMVEC human microvascular endothelial cells. Marconcini, L. et al. (1999) Proc. Natl. Acad. Sci. USA 96:9671. The ED50 for this effect is 0.2-0.8 µg/mL. Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human VEGF R3/Flt‑4 Fc Chimera (Catalog # 349-F4) binds Recombinant Human VEGF-C with an apparent Kd <15 nM.
Source
Mouse myeloma cell line, NS0-derived human VEGF-C protein
Thr103-Arg227, with a C-terminal 10-His tag
Accession #
P49767
N-terminal Sequence
Analysis
Thr103
Predicted Molecular Mass
15.5 kDa
SDS-PAGE
21 kDa, reducing conditions

Product Datasheets

You must select a language.

x

2179-VC (with carrier)

Product Datasheet
COA
SDS

You must select a language.

x

2179-VC/CF (carrier free)

Discontinued Product

2179-VC

Formulation Lyophilized from a 0.2 μm filtered solution in HCl with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: VEGF-C

Vascular endothelial growth factor C (VEGF-C) and VEGF-D constitute a subfamily of the angiogenic VEGF angiogenic factors (1). VEGF-C is synthesized as a 58 kDa molecule that consists of a VEGF homolgy domain (VHD) flanked by N- and C-terminal propeptides. The proprotein undergoes covalent homodimerization and stepwise proteolytic processing to generate ligands with increasing affinity for VEGF R3/Flt-4 (2-4). Fully processed VEGF-C containing just the 21 kDa VHD can additionally bind and activate VEGF R2/KDR/Flk-1 (2, 4). Fully processed human VEGF-C shares 98% amino acid sequence identity with mouse and rat VEGF-C. VEGF-C interactions with VEGF R3 are critical for lymphangiogenesis (5-8). VEGF-C and VEGF R3 are usually co-expressed at sites with lymphatic vessel sprouting, in the embryo, and in various pathological conditions. Over-expression of VEGF-C in tumor cells induces tumoral lymphatic hyperplasia, resulting in enhanced lymph flow and metastasis to regional lymph nodes (9-12). It also induces physiological and intratumoral neoangiogenesis and vessel sprouting through interactions with VEGF R2 (8, 13, 14).

References
  1. Chen, J.-C. et al. (2013) Int. J. Mol. Sci. 14:88.
  2. Joukov, V. et al. (1996) EMBO J. 15:290.
  3. Kukk, E. et al. (1996) Development 122:3829.
  4. Joukov, V. et al. (1997) EMBO J. 16:3898.
  5. Karkkainen, M. et al. (2004) Nat. Immunol. 5:74.
  6. Jeltsch, M. et al. (1997) Science 276:1423.
  7. Makinen, T. et al. (2001) Nat. Med. 7:199.
  8. Laakkonen, P. et al. (2007) Cancer Res. 67:593.
  9. Hoshida, T. et al. (2006) Cancer Res. 66:8065.
  10. Mandriota, S.J. et al. (2001) EMBO J. 20:672.
  11. Skobe, M. et al. (2001) Nat. Med. 7:192.
  12. Padera, T.P. et al. (2002) Science 296:1883.
  13. Tammela, T. et al. (2008) Nature 454:656.
  14. Cao, Y. et al. (1998) Proc. Natl. Acad. Sci. 95:14389.
Long Name
Vascular Endothelial Growth Factor C
Entrez Gene IDs
7424 (Human); 22341 (Mouse)
Alternate Names
Flt4 ligand; Flt4-L; vascular endothelial growth factor C; Vascular endothelial growth factor-related protein; VEGFC; VEGF-C; VRPFLT4 ligand DHM

Citations for Recombinant Human VEGF-C Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

25 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema
    Authors: D Sz?ke, G Kovács, É Kemecsei, L Bálint, K Szoták-Ajt, P Aradi, A Styevkóné, BL Mui, YK Tam, TD Madden, K Karikó, RP Kataru, MJ Hope, D Weissman, BJ Mehrara, N Pardi, Z Jakus
    Nature Communications, 2021-06-08;12(1):3460.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  2. Atypical cadherin Fat4 orchestrates lymphatic endothelial cell polarity in response to flow
    Authors: KL Betterman, DL Sutton, GA Secker, J Kazenwadel, A Oszmiana, L Lim, N Miura, L Sorokin, BM Hogan, ML Kahn, H McNeill, NL Harvey
    J. Clin. Invest., 2020-06-01;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  3. MicroRNA-155 induction via TNF-? and IFN-? suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells
    Authors: D Yee, KM Shah, MC Coles, TV Sharp, D Lagos
    J. Biol. Chem., 2017-10-24;292(50):20683-20693.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  4. Lymphatic Endothelial Cells under Mechanical Stress: Altered Expression of Inflammatory Cytokines and Fibrosis
    Authors: S Wang, D Nie, JP Rubin, L Kokai
    Lymphat Res Biol, 2017-05-09;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  5. PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells
    Authors: P Nandi, GV Girish, M Majumder, X Xin, E Tutunea-Fa, PK Lala
    BMC Cancer, 2017-01-05;17(1):11.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  6. Downregulation of proinflammatory cytokines in HTLV-1-infected T cells by Resveratrol
    J Exp Clin Cancer Res, 2016-07-22;35(1):118.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  7. EPHB4 kinase-inactivating mutations cause autosomal dominant lymphatic-related hydrops fetalis
    J Clin Invest, 2016-07-11;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  8. Bone marrow-derived mesenchymal stem cells drive lymphangiogenesis.
    Authors: Maertens L, Erpicum C, Detry B, Blacher S, Lenoir B, Carnet O, Pequeux C, Cataldo D, Lecomte J, Paupert J, Noel A
    PLoS ONE, 2014-09-15;9(9):e106976.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  9. VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease.
    Authors: D'Alessio S, Correale C, Tacconi C, Gandelli A, Pietrogrande G, Vetrano S, Genua M, Arena V, Spinelli A, Peyrin-Biroulet L, Fiocchi C, Danese S
    J Clin Invest, 2014-08-08;124(9):3863-78.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  10. The docking protein FRS2alpha is a critical regulator of VEGF receptors signaling.
    Authors: Chen P, Qin L, Zhuang Z, Tellides G, Lax I, Schlessinger J, Simons M
    Proc Natl Acad Sci U S A, 2014-04-02;111(15):5514-9.
    Species: Human, Mouse
    Sample Types: In Vivo, Whole Cells
    Applications: Bioassay, In Vivo
  11. Effects of adenosine on lymphangiogenesis.
    Authors: Lenoir B, Wagner D, Blacher S, Sala-Newby G, Newby A, Noel A, Devaux Y
    PLoS ONE, 2014-03-20;9(3):e92715.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  12. ADAMTS1 inhibits lymphangiogenesis by attenuating phosphorylation of the lymphatic endothelial cell-specific VEGF receptor.
    Authors: Inagaki J, Takahashi K, Ogawa H, Asano K, Faruk Hatipoglu O, Cilek M, Obika M, Ohtsuki T, Hofmann M, Kusachi S, Ninomiya Y, Hirohata S
    Exp Cell Res, 2014-03-11;323(2):263-75.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  13. Bone morphogenetic protein 2 signaling negatively modulates lymphatic development in vertebrate embryos.
    Authors: Dunworth, William, Cardona-Costa, Jose, Bozkulak, Esra Cag, Kim, Jun-Dae, Meadows, Stryder, Fischer, Johanna, Wang, Yeqi, Cleaver, Ondine, Qyang, Yibing, Ober, Elke A, Jin, Suk-Won
    Circ Res, 2013-10-11;114(1):56-66.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  14. COUP-TFII orchestrates venous and lymphatic endothelial identity by homo- or hetero-dimerisation with PROX1.
    Authors: Aranguren, Xabier L, Beerens, Manu, Coppiello, Giulia, Wiese, Cornelia, Vandersmissen, Ine, Lo Nigro, Antonio, Verfaillie, Catherin, Gessler, Manfred, Luttun, Aernout
    J Cell Sci, 2013-01-23;126(0):1164-75.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  15. Deletion of tetraspanin CD9 diminishes lymphangiogenesis in vivo and in vitro.
    Authors: Iwasaki T, Takeda Y, Maruyama K, Yokosaki Y, Tsujino K, Tetsumoto S, Kuhara H, Nakanishi K, Otani Y, Jin Y, Kohmo S, Hirata H, Takahashi R, Suzuki M, Inoue K, Nagatomo I, Goya S, Kijima T, Kumagai T, Tachibana I, Kawase I, Kumanogoh A
    J Biol Chem, 2012-12-05;288(4):2118-31.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: Bioassay
  16. The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain.
    Authors: Martino MM, Hubbell JA
    FASEB J., 2010-07-29;24(12):4711-21.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Surface Plasmon Resonance
  17. Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway.
    Authors: Chien MH, Ku CC, Johansson G, Chen MW, Hsiao M, Su JL, Inoue H, Hua KT, Wei LH, Kuo ML
    Carcinogenesis, 2009-12-01;30(12):2005-13.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  18. Lymphangiogenesis and angiogenesis: concurrence and/or dependence? Studies in inbred mouse strains.
    Authors: Nakao S, Maruyama K, Zandi S, Melhorn MI, Taher M, Noda K, Nusayr E, Doetschman T, Hafezi-Moghadam A
    FASEB J., 2009-10-26;24(2):504-13.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  19. Autocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells.
    Authors: Matsuura M, Onimaru M, Yonemitsu Y, Suzuki H, Nakano T, Ishibashi H, Shirasuna K, Sueishi K
    Am. J. Pathol., 2009-09-24;175(4):1709-21.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  20. alpha2beta1 integrin expression in the tumor microenvironment enhances tumor angiogenesis in a tumor cell-specific manner.
    Authors: Zhang Z, Ramirez NE, Yankeelov TE, Li Z, Ford LE, Qi Y, Pozzi A, Zutter MM
    Blood, 2007-11-27;111(4):1980-8.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  21. Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells.
    Authors: Vart RJ, Nikitenko LL, Lagos D, Trotter MW, Cannon M, Bourboulia D, Gratrix F, Takeuchi Y, Boshoff C
    Cancer Res., 2007-05-01;67(9):4042-51.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  22. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis.
    Authors: Huber S, Bruns CJ, Schmid G, Hermann PC, Conrad C, Niess H, Huss R, Graeb C, Jauch KW, Heeschen C, Guba M
    Kidney Int., 2007-02-14;71(8):771-7.
    Species: Human, Mouse
    Sample Types: In Vivo, Whole Cells
    Applications: Bioassay, In Vivo
  23. Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3A.
    Authors: Narazaki M, Tosato G
    Blood, 2006-01-19;107(10):3892-901.
    Applications: ELISA (Standard)
  24. A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3.
    Authors: Jimenez X, Lu D, Brennan L, Persaud K, Liu M, Miao H, Witte L, Zhu Z
    Mol. Cancer Ther., 2005-03-01;4(3):427-34.
    Species: Bovine, Human
    Sample Types: Antibody, Whole Cells
    Applications: Bioassay, ELISA (Capture)
  25. Microvascular patterning is controlled by fine-tuning the Akt signal.
    Authors: Sun JF, Phung T, Shiojima I, Felske T, Upalakalin JN, Feng D, Kornaga T, Dor T, Dvorak AM, Walsh K, Benjamin LE
    Proc. Natl. Acad. Sci. U.S.A., 2004-12-20;102(1):128-33.
    Species: Bovine
    Sample Types: Whole Cells
    Applications: Bioassay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human VEGF-C Protein

Average Rating: 4 (Based on 2 Reviews)

5 Star
0%
4 Star
100%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Recombinant Human VEGF-C Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Recombinant Human VEGF-C Protein
By Anonymous on 12/05/2021
Application: Cell migration/motility
Reason for Rating: Endothelial cells were treated with VEGFC to test its effect on migration.
Cell migration/motility Recombinant Human VEGF-C Protein 2179-VC
Recombinant Human VEGF-C Protein
By Anonymous on 02/08/2018
Application: SDS-PAGE Control
SDS-PAGE Control Recombinant Human VEGF-C Protein 2179-VC